Sandoz Partner Samsung Bioepis Settles On Stelara In US
Partners Snag Third-Earliest Launch Date So Far For Biosimilar Ustekinumab
Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.
You may also be interested in...
With competition to Stelara due to kick in midway through 2024, the brand now represents a $10bn+ target for biosimilars, according to the latest figures from J&J.
A further US settlement agreement over Stelara has been struck with originator Janssen, with Accord BioPharma revealing the deal at the same time as it announced that a filing for its Dong-A/Meiji Seika-partnered DMB-3115 biosimilar ustekinumab candidate had been accepted for review by the FDA.
An eventful 2023 for Sandoz saw multiple major deals and key launches, with the year culminating in the firm’s long-awaited spinoff from parent company Novartis in October.